Refine
Document Type
- Article (65)
- Conference Proceeding (1)
Has Fulltext
- yes (66)
Is part of the Bibliography
- no (66)
Keywords
- Epilepsy (18)
- Seizure (10)
- epilepsy (9)
- seizure (7)
- Epilepsie (5)
- Dravet syndrome (4)
- Epileptischer Anfall (4)
- Prevalence (4)
- Burden of illness (3)
- Epileptische Anfälle (3)
- Healthcare costs (3)
- Quality of life (3)
- Status epilepticus (3)
- TSC (3)
- fenfluramine (3)
- levetiracetam (3)
- Acute seizure plan (2)
- Akuter Anfallsplan (2)
- Anti-seizure medication (2)
- Antikonvulsiva (2)
- Cannabidiol (2)
- Clinical Global Impression of Change (2)
- Corona (2)
- Costs (2)
- Encephalopathy (2)
- Gezielte Therapie (2)
- Healthcare resource utilization (2)
- Neurology (2)
- Pandemic (2)
- Pandemie (2)
- Personalisierte translationale Therapie (2)
- Personalized medicine (2)
- Rescue medication (2)
- SARS-CoV‑2 (2)
- SV2A (2)
- Seizures (2)
- Selbstmanagement (2)
- Self-management (2)
- Tailored therapy (2)
- Targeted therapy (2)
- adverse events (2)
- anticonvulsants (2)
- antiseizure medication (2)
- convulsive seizures (2)
- epidemiology (2)
- morbidity (2)
- real-world (2)
- refractory (2)
- secondary data analysis (2)
- seizures (2)
- status epilepticus (2)
- Acute-on-chronic subdural hematoma (1)
- Anfall (1)
- Anfallsunterbrechende (1)
- Anfallsunterbrechende Medikamente (1)
- Angiomyolipoma (1)
- Anticonvulsant (1)
- Anticonvulsants (1)
- Antiseizure medication (1)
- Antiseizure medication Instructions for action (1)
- BFIS (1)
- CLOCC (1)
- COVID-19 (1)
- Cerebrovascular disorders (1)
- Comorbidity (1)
- Cross- sectional study (1)
- DRG (1)
- DWI (1)
- Depression (1)
- Diagnosis related groups (1)
- Digitalisierung (1)
- Digitalization (1)
- Disconnection (1)
- Diskonnektion (1)
- Drugs (1)
- Enzephalopathie (1)
- Epidemiology (1)
- Epilepsiechirurgie (1)
- Epilepsiezentren (1)
- Epilepsy Acute seizure plan Antiseizure medication Instructions for action Self-management (1)
- Epilepsy center (1)
- Epilepsy centers (1)
- Epilepsy surgery (1)
- Epileptic seizure (1)
- Epileptic seizures (1)
- Everolimus (1)
- Falls (1)
- Focal onset seizure (1)
- Fracture (1)
- Gastric motility (1)
- Gelastic seizures (1)
- Gelastische Anfälle (1)
- Genetics (1)
- Germany (1)
- Gesundheitspolitische Zuständigkeit (1)
- Gesundheitsökonomie (1)
- Gut (1)
- HEOR (1)
- Handlungsanweisungen (1)
- Health economics (1)
- Healthcare resource utilisation (1)
- Healthcare structure (1)
- Incidence (1)
- Inpatient hospital cases (1)
- Instructions for action (1)
- Krankheitskosten (1)
- Lafora disease (1)
- Large vessel occlusion (1)
- Lebensqualität (1)
- Lennox-Gastaut syndrome (1)
- Limitation of therapy (1)
- Ländlicher Raum (1)
- MRI (1)
- MRI-negative epilepsy (1)
- MTOR inhibitor (1)
- Medikamente (1)
- Medikamente Handlungsanweisungen (1)
- Minimal-invasiv (1)
- Minimally invasive (1)
- Morbidity (1)
- Non-expert MRI (1)
- Outcome (1)
- PKD (1)
- PKD/IC (1)
- PRRT2 (1)
- Pediatrics (1)
- Psychology (1)
- Pädiatrie (1)
- Querschnittsstudie (1)
- RESLES (1)
- Real-time MRI (1)
- Recurrence (1)
- Recurrent episodes (1)
- Referral (1)
- Responsibility of healthcare policy (1)
- Rhabdomyoma (1)
- Risk factors (1)
- Rural areas (1)
- STAMPE2 (1)
- SUDEP (1)
- Shoulder luxation (1)
- Sociodemographic characteristics (1)
- Stationäre Krankenhausfälle (1)
- Stroke (1)
- Stroke unit (1)
- Subependymal giant cell astrocytoma (1)
- TSC-associated neuropsychiatric disorders (1)
- Tele-EEG (1)
- Tele-consultation (1)
- Telekonsil (1)
- Therapielimitierung (1)
- Treatment costs (1)
- Tuberous sclerosis complex (1)
- Vagus nerve (1)
- Vagus nerve stimulation (1)
- Versorgungsstruktur (1)
- Wounds and injuries (1)
- accident (1)
- alteplase (1)
- anticonvulsant (1)
- antiepileptic drug (1)
- asymptomatic temporal encephaloceles (1)
- brain metastases (1)
- burden of illness (1)
- cerebral pseudoprogression (1)
- cluttering (1)
- cognitive decline (1)
- complication (1)
- corpus callosum (1)
- cost containment (1)
- cost of illness (1)
- counseling (1)
- depression (1)
- economic burden (1)
- encephalopathy (1)
- endovascular thrombectomy (1)
- epilepsy surgery (1)
- epileptic encephalopathies (1)
- epileptic encephalopathy (1)
- epileptogenesis (1)
- everolimus (1)
- falls (1)
- familial infantile epilepsy (1)
- genetics (1)
- health care (1)
- healthcare systems (1)
- hemiplegic migraine (1)
- immune checkpoint inhibitors (ICI) (1)
- immune related adverse events (irAE) (1)
- immunotherapy (1)
- improvement in quality of life (1)
- infection (1)
- inpatient hospital admissions (1)
- juvenile myoclonic epilepsy (1)
- ketogenic diet (1)
- laceration (1)
- lockdown (1)
- longitudinal follow-up after epilepsy surgery (1)
- mTOR inhibitor (1)
- mTORC1 (1)
- mechanical recanalization (1)
- medical informatics initiative (1)
- meningioma (1)
- mesial temporal lobe epilepsy (1)
- minimal clinically important difference (1)
- minimally invasive therapy (1)
- mortality (1)
- neurocritical care (1)
- neurological complication (1)
- neurological side effects (1)
- oedema (1)
- pandemic (1)
- pharmacoresistance (1)
- phenotypic spectrum (1)
- population-based (1)
- progressive myoclonus epilepsy (1)
- quality of life (1)
- rare diseases (1)
- reliable change index (1)
- standardized regression-based change norms (1)
- stiripentol (1)
- stuttering (1)
- tVNS (1)
- temporal encephaloceles (1)
- temporal lobe epilepsy (1)
- thermal ablation (1)
- thrombolysis (1)
- tuberous sclerosis complex (1)
- university hospitals (1)
Institute
- Medizin (66)
- Georg-Speyer-Haus (1)
- Pharmazie (1)
Background: Epilepsy surgery is an established treatment for drug-resistant focal epilepsy (DRFE) that results in seizure freedom in about 60% of patients. Correctly identifying an epileptogenic lesion in magnetic resonance imaging (MRI) is challenging but highly relevant since it improves the likelihood of being referred for presurgical diagnosis. The epileptogenic lesion’s etiology directly relates to the surgical intervention’s indication and outcome. Therefore, it is vital to correctly identify epileptogenic lesions and their etiology presurgically.
Methods: We compared the final histopathological diagnoses of all patients with DRFE undergoing epilepsy surgery at our center between 2015 and 2021 with their MRI diagnoses before and after presurgical diagnosis at our epilepsy center, including MRI evaluations by expert epilepsy neuroradiologists. Additionally, we analyzed the outcome of different subgroups.
Results: This study included 132 patients. The discordance between histopathology and MRI diagnoses significantly decreased from 61.3% for non-expert MRI evaluations (NEMRIs) to 22.1% for epilepsy center MRI evaluations (ECMRIs; p < 0.0001). The MRI-sensitivity improved significantly from 68.6% for NEMRIs to 97.7% for ECMRIs (p < 0.0001). Identifying focal cortical dysplasia (FCD) and amygdala dysplasia was the most challenging for both subgroups. 65.5% of patients with negative NEMRI were seizure-free 12 months postoperatively, no patient with negative ECMRI achieved seizure-freedom. The mean duration of epilepsy until surgical intervention was 13.6 years in patients with an initial negative NEMRI and 9.5 years in patients with a recognized lesion in NEMRI.
Conclusions: This study provides evidence that for patients with DRFE—especially those with initial negative findings in a non-expert MRI—an early consultation at an epilepsy center, including an ECMRI, is important for identifying candidates for epilepsy surgery. NEMRI-negative findings preoperatively do not preclude seizure freedom postoperatively. Therefore, patients with DRFE that remain MRI-negative after initial NEMRI should be referred to an epilepsy center for presurgical evaluation. Nonreferral based on NEMRI negativity may harm such patients and delay surgical intervention. However, ECMRI-negative patients have a reduced chance of becoming seizure-free after epilepsy surgery. Further improvements in MRI technique and evaluation are needed and should be directed towards improving sensitivity for FCDs and amygdala dysplasias.
Background: Patients with epilepsy often require a specialized treatment, which may differ because of the responsibility of the federal states for healthcare policy in Germany.
Objective: State-specific differences in healthcare structures based on inpatient hospital cases of epilepsy patients between 2000 and 2020 in relation to specialized treatment offers.
Material and methods: The inpatient hospital cases of the German federal states were evaluated using the Friedman test and time series trend analysis. A state-specific inpatient undertreatment or overtreatment of inpatient hospital cases outside the registered state was analyzed by comparing residence-related and treatment site-related case numbers with a threshold of ±5%.
Results: After age adjustment, significantly more inpatient cases were found in the “new states” compared to the “old states” (p < 0.001); the highest number of cases nationwide was found in Saarland with 224.8 ± 11.5 cases per 100,000 inhabitants. The trend analysis showed an increase in cases until the end of 2016 with a trend reversal from 2017 and a further significant decrease in hospital cases in the COVID year 2020. A relative inpatient undertreatment was shown for Brandenburg, Lower Saxony, Rhineland-Palatinate, Saxony-Anhalt, Schleswig-Holstein and Thuringia. Additional, possibly compensatory, inpatient care was found for all city states (Hamburg, Bremen and Berlin) and Baden-Wuerttemberg. In federal states with a relative inpatient undertreatment and/or high inpatient hospital case numbers, there was often a lower availability of specialized epilepsy centers, specialized outpatient clinics and epilepsy outpatient clinics.
Conclusion: In Germany there are state-specific differences in the structure of care, with higher inpatient hospital care in the “new states” and Saarland. In addition, there were federal states with disproportionately higher treatment of patients not registered in this federal state. A potential influencing factor may be the availability of centers with specialized treatment for epilepsy patients.
Der Status epilepticus (SE) stellt eine schwerwiegende akute Erkrankung dar, die eine frühzeitige und gezielte Therapie erfordert. Insbesondere der refraktäre SE (RSE) sowie der superrefraktäre SE (SRSE) sind bereits bei jungen Menschen eine interdisziplinäre therapeutische Herausforderung. Bei Patienten in höherem Lebensalter sind hierbei weitere relevante Aspekte zu beachten, die sich einerseits aufgrund einer abweichenden Pharmakokinetik und -dynamik ergeben, andererseits aber auch aus Komorbiditäten, Polypharmazie und möglichen medizinischen Therapielimitationen bzw. Patientenpräferenzen resultieren. Ziel dieses Artikels ist es, diese besonderen Aspekte im Rahmen der SE-Versorgung älterer Menschen aufzuarbeiten und potenzielle Therapiestrategien jenseits der Leitlinie aufzuzeigen. Insbesondere wird hierbei auf alternative Applikationswege und mögliche konservative Eskalationsformen der Therapie eingegangen, die v. a. bei relevant vorerkrankten Patienten von Bedeutung sind, bei denen eine intensivmedizinische Behandlung die ohnehin schon hohe Mortalität des SE im gehobenen Alter weiter erhöhen würde. Mit unterschiedlichen parenteralen Applikationsformen von Benzodiazepinen im SE sowie dem mittlerweile gut beschriebenen Einsatz weiterer Antikonvulsiva wie Brivaracetam, Perampanel, Stiripentol, Topiramat und Zonisamid in RSE und SRSE stehen auch für diese vulnerable Patientengruppe adäquate Therapieoptionen zur Verfügung. Nichtsdestotrotz sollte in der Therapie des SE im gehobenen Alter insbesondere in Anbetracht der per se hohen Mortalität verstärkt auf Patientenpräferenzen und medizinethische Aspekte geachtet werden.
The developmental and epileptic encephalopathies encompass a group of rare syndromes characterised by severe drug-resistant epilepsy with onset in childhood and significant neurodevelopmental comorbidities. The latter include intellectual disability, developmental delay, behavioural problems including attention-deficit hyperactivity disorder and autism spectrum disorder, psychiatric problems including anxiety and depression, speech impairment and sleep problems. Classical examples of developmental and epileptic encephalopathies include Dravet syndrome, Lennox–Gastaut syndrome and tuberous sclerosis complex. The mainstay of treatment is with multiple anti-seizure medications (ASMs); however, the ASMs themselves can be associated with psychobehavioural adverse events, and effects (negative or positive) on cognition and sleep. We have performed a targeted literature review of ASMs commonly used in the treatment of developmental and epileptic encephalopathies to discuss the latest evidence on their effects on behaviour, mood, cognition, sedation and sleep. The ASMs include valproate (VPA), clobazam, topiramate (TPM), cannabidiol (CBD), fenfluramine (FFA), levetiracetam (LEV), brivaracetam (BRV), zonisamide (ZNS), perampanel (PER), ethosuximide, stiripentol, lamotrigine (LTG), rufinamide, vigabatrin, lacosamide (LCM) and everolimus. Bromide, felbamate and other sodium channel ASMs are discussed briefly. Overall, the current evidence suggest that LEV, PER and to a lesser extent BRV are associated with psychobehavioural adverse events including aggressiveness and irritability; TPM and to a lesser extent ZNS are associated with language impairment and cognitive dulling/memory problems. Patients with a history of behavioural and psychiatric comorbidities may be more at risk of developing psychobehavioural adverse events. Topiramate and ZNS may be associated with negative effects in some aspects of cognition; CBD, FFA, LEV, BRV and LTG may have some positive effects, while the remaining ASMs do not appear to have a detrimental effect. All the ASMs are associated with sedation to a certain extent, which is pronounced during uptitration. Cannabidiol, PER and pregabalin may be associated with improvements in sleep, LTG is associated with insomnia, while VPA, TPM, LEV, ZNS and LCM do not appear to have detrimental effects. There was variability in the extent of evidence for each ASM: for many first-generation and some second-generation ASMs, there is scant documented evidence; however, their extensive use suggests favourable tolerability and safety (e.g. VPA); second-generation and some third-generation ASMs tend to have the most robust evidence documented over several years of use (TPM, LEV, PER, ZNS, BRV), while evidence is still being generated for newer ASMs such as CBD and FFA. Finally, we discuss how a variety of factors can affect mood, behaviour and cognition, and untangling the associations between the effects of the underlying syndrome and those of the ASMs can be challenging. In particular, there is enormous heterogeneity in cognitive, behavioural and developmental impairments that is complex and can change naturally over time; there is a lack of standardised instruments for evaluating these outcomes in developmental and epileptic encephalopathies, with a reliance on subjective evaluations by proxy (caregivers); and treatment regimes are complex involving multiple ASMs as well as other drugs.
Eine barrierefreie Teilnahme am alltäglichen Leben stellt für Menschen mit aktiver Epilepsie häufig eine Herausforderung dar. Epileptische Anfälle können in Kindergarten, Schule und am Arbeitsplatz sowie im häuslichen Umfeld Unsicherheit und Überforderung hervorrufen. Individuell erstellte Pläne für Betreuende, Angehörige, Aufsichtspersonen und den Rettungsdienst sollen im Falle eines akuten Anfalls geeignete Handlungsanweisungen geben. Bisher gibt es hierfür im deutschsprachigen Raum keine standardisierten Vorlagen. Mit den Handlungsplänen bei epileptischen Anfällen für Laien (HEAL) bzw. Therapeuten (HEAT) werden hier 2 Formulare vorgestellt, die zum einen eine standardisierte Grundlage bieten und andererseits leicht auf den individuellen Bedarf angepasst werden können.
Eine barrierefreie Teilnahme am alltäglichen Leben stellt für Menschen mit aktiver Epilepsie häufig eine Herausforderung dar. Epileptische Anfälle können in Kindergarten, Schule und am Arbeitsplatz sowie im häuslichen Umfeld Unsicherheit und Überforderung hervorrufen. Individuell erstellte Pläne für Betreuende, Angehörige, Aufsichtspersonen und den Rettungsdienst sollen im Falle eines akuten Anfalls geeignete Handlungsanweisungen geben. Bisher gibt es hierfür im deutschsprachigen Raum keine standardisierten Vorlagen. Mit den Handlungsplänen bei epileptischen Anfällen für Laien (HEAL) bzw. Therapeuten (HEAT) werden hier 2 Formulare vorgestellt, die zum einen eine standardisierte Grundlage bieten und andererseits leicht auf den individuellen Bedarf angepasst werden können.
Tuberous sclerosis complex (TSC) is a rare genetic disease that is, besides cutaneous and visceral organ manifestations, typically associated with a severe, usually drug refractory epilepsy at a very early stage of the disease. Due to its direct effect on the mTOR signaling pathway dysregulated by TSC and its synergistic effects on other organ manifestations, the rapamycin derivative everolimus (EVE) is increasingly being used. The aim of this systematic review is to evaluate the efficacy, safety and tolerability of EVE in patients with TSC-associated, refractory epilepsy.
The present study aims to report the currently available epidemiology of focal onset seizures in children aged >1 month to 4 years with the help of a literature review. The terms ‘seizure*’ OR ‘epilepsy’ combined with pediatric and epidemiology terms were used to search Embase, PubMed, and Web of Science up to November 16, 2021. Due to the scarcity of epidemiology data on focal onset seizures, the incidence and prevalence were estimated using the proportion of focal onset seizures in epilepsy patients from the most recently published articles. The estimated annual incidence per 100,000 children of focal onset seizures in children of 0–4 years of age ranged from 25.1 (95 % confidence interval [CI] 18.9–32.7) in the United Kingdom to 111.8 in the United States. The estimated period prevalence of focal onset seizures in children 0–4 years of age ranged from 0.15 % (99 % CI 0.13–0.18) in Canada to 0.61 % in the United States. Neurodevelopmental outcomes and psychiatric disorders were the most commonly reported comorbidities in children with epilepsy of age 0–4 years. Presence of focal onset seizures in children with different epilepsy syndromes needs to be thoroughly considered in the treatment planning of this population of interest.
Background: Multiple studies have focused on medical and pharmacological treatments and outcome predictors of patients with status epilepticus (SE). However, a sufficient understanding of recurrent episodes of SE is lacking. Therefore, we reviewed recurrent SE episodes to investigate their clinical characteristics and outcomes in patients with relapses.
Methods: In this retrospective, multicenter study, we reviewed recurrent SE patient data covering 2011 to 2017 from the university hospitals of Frankfurt and Marburg, Germany. Clinical characteristics and outcome variables were compared among the first and subsequent SE episodes using a standardized form for data collection.
Results: We identified 120 recurrent SE episodes in 80 patients (10.2% of all 1177 episodes). The mean age at the first SE episode was 62.2 years (median 66.5; SD 19.3; range 21–91), and 42 of these patients were male (52.5%). A mean of 262.4 days passed between the first and the second episode. Tonic–clonic seizure semiology and a cerebrovascular disease etiology were predominant in initial and recurrent episodes. After subsequent episodes, patients showed increased disability as indicated by the modified Rankin Scale (mRS), and 9 out of 80 patients died during the second episode (11.3%). Increases in refractory and super-refractory SE (RSE and SRSE, respectively) were noted during the second episode, and the occurrence of a non-refractory SE (NRSE) during the first SE episode did not necessarily provide a protective marker for subsequent non-refractory episodes. An increase in the use of intravenous-available anti-seizure medication (ASM) was observed in the treatment of SE patients. Patients were discharged from hospital with a mean of 2.8 ± 1.0 ASMs after the second SE episode and 2.1 ± 1.2 ASMs after the first episode. Levetiracetam was the most common ASM used before admission and on discharge for SE patients.
Conclusions: This retrospective, multicenter study used the mRS to demonstrate worsened outcomes of patients at consecutive SE episodes. ASM accumulations after subsequent SE episodes were registered over the study period. The study results underline the necessity for improved clinical follow-ups and outpatient care to reduce the health care burden from recurrent SE episodes.